Pepstatin, an inhibitor of acid kininogenases and ascites retardant in neoplastic disease.
Evidence is reviewed that pepstatin, an inhibitor of acid kininogenases such as cathepsin D, may be an effective therapeutic agent in retarding ascites accumulation in certain cancers. The evidence for this conclusion is based on the actions of pepstatin in retarding ascites in six different tumor strains inoculated into various species of mice, as well as the demonstration that cathepsin D activity is reduced in vivo in several organs following pepstatin administration. The latter is significant since we have postulated that ascites formation, in good part, is due to leukokinin formation, which is catalyzed by cellular-released cathepsin D.
D000818:Animals; D001201:Ascites / Q000378:metabolism / Q000517:prevention & control*; D002403:Cathepsins / Q000037:antagonists & inhibitors; D051379:Mice; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D009842:Oligopeptides / Q000627:therapeutic use*; D010436:Pepstatins / Q000494:pharmacology / Q000627:therapeutic use*; D014405:Tuftsin / Q000037:antagonists & inhibitors* / Q000378:metabolism; D005719:gamma-Globulins / Q000037:antagonists & inhibitors*
D009842:Oligopeptides; D010436:Pepstatins; D005719:gamma-Globulins; D002403:Cathepsins; D014405:Tuftsin